Open AccessThe role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
Author(s) -
Jaeha Lee,
Jin Han Park,
Ji Hoon Jang,
Se Hun Kim,
Sung Yong Hong,
Woon Heo,
Donghwan Lee,
Hye Sook Choi,
Ki Hoon Kim,
Hang-Jea Jang
Publication year - 2022
Publication title -
acute and critical care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.345
H-Index - 4
eISSN - 2586-6060
pISSN - 2586-6052
DOI - 10.4266/acc.2021.01312
Subject(s) - medicine , extracorporeal membrane oxygenation , partial thromboplastin time , heparin , anesthesia , thrombosis , activated clotting time , anticoagulant , medical record , surgery , platelet
Anticoagulation during extracorporeal membrane oxygenation (ECMO) usually is required to prevent thrombosis. The aim of this study was to investigate the usefulness of nafamostat mesilate (NM) as a regional anticoagulant during veno-arterial ECMO (VA-ECMO) treatment.